These findings suggest that the loss of CCM2 affects the activity of PRC1/2 and is associated with CCM-related pathological phenotypes, affecting angiogenesis, Rho protein signaling, and EC migration, among others. The gene discussed is RHO; the disease is cerebral cavernous malformation.